Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
107.00
+12.14 (12.80%)
At close: May 2, 2024, 4:00 PM
107.02
+0.02 (0.02%)
After-hours: May 2, 2024, 5:46 PM EDT
Blueprint Medicines Employees
Blueprint Medicines had 655 employees on December 31, 2023. The number of employees increased by 14 or 2.18% compared to the previous year.
Employees
655
Change (1Y)
14
Growth (1Y)
2.18%
Revenue / Employee
$380,733
Profits / Employee
-$774,021
Market Cap
6.55B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 655 | 14 | 2.18% |
Dec 31, 2022 | 641 | 146 | 29.49% |
Dec 31, 2021 | 495 | 66 | 15.38% |
Dec 31, 2020 | 429 | 46 | 12.01% |
Dec 31, 2019 | 383 | 166 | 76.50% |
Dec 31, 2018 | 217 | 68 | 45.64% |
Dec 31, 2017 | 149 | 43 | 40.57% |
Dec 31, 2016 | 106 | 25 | 30.86% |
Dec 31, 2015 | 81 | 20 | 32.79% |
Dec 31, 2014 | 61 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Grifols | 23,737 |
DENTSPLY SIRONA | 15,000 |
Elanco Animal Health | 9,800 |
Option Care Health | 7,802 |
Ionis Pharmaceuticals | 927 |
Apellis Pharmaceuticals | 702 |
ImmunityBio | 628 |
BPMC News
- 11 hours ago - Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PRNewsWire
- 14 days ago - Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 - PRNewsWire
- 21 days ago - Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics - PRNewsWire
- 4 weeks ago - Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 2 months ago - Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting - PRNewsWire
- 2 months ago - Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results - PRNewsWire
- 3 months ago - Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 - PRNewsWire
- 4 months ago - VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug Discovery - Business Wire